Hematologic Malignancies treatment at the University of Maryland Marlene and Stewart Greenebaum Cancer Center is built on a long-standing tradition of excellence. From its inception as an extramural program of the National Cancer Institute, UMGCC has been at the forefront of developing and testing new therapies for hematologic malignancies.
With one of the largest experimental therapeutics programs on the East Coast, we offer experimental therapies for all stages of leukemia, lymphoma, Hodgkin's disease and multiple myeloma. Our center is a member of the Myeloproliferative Disorders Research Consortium, an NIH-funded international clinical trials group focusing on myeloproliferative disorders.
Our team of experts includes internationally and nationally recognized leaders in this field, and we continue to set the standard for treating patients with:
- Acute and chronic leukemia
- Lymphomas, including Hodgkin's disease
- Multiple myeloma and other similar disease disorders
- AIDS-related lymphomas
Working with referring physicians to provide patients with the best possible care, we treat all types of hematologic malignancies. Our experts work together throughout the treatment process to ensure that patients receive the highly individualized program of care they need while undergoing complex, aggressive therapies.
This page was last updated: July 13, 2015